Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Glaxosmithkline Plc In 50:50 JV With Biological E For Developing Paediatric Vaccine-The Economic Times


Monday, 28 Jan 2013 03:04pm EST 

The Economic Times reported that Glaxosmithkline Plc has teamed up with Hyderabad-based vaccines company Biological E Ltd for early-stage research and development of a six-in-one combination paediatric vaccine to help protect children in India and other developing markets. Under the equal joint venture agreement, both companies will develop a six-in-one vaccine for polio and other infectious diseases, reinforcing their commitment to work with the World Health Organisation (WHO) to eradicate polio. Under the equal joint venture agreement, both companies will develop a six-in-one vaccine for polio and other infectious diseases, reinforcing their commitment to work with the World Health Organisation (WHO) to eradicate polio. 

Company Quote

48.37
-0.1 -0.21%
31 Jul 2014